Pancreatitis & GLP-1 Medications

Pancreatitis is inflammation of the pancreas, an organ behind the stomach that produces enzymes for digestion and hormones like insulin. Acute pancreatitis causes sudden, severe upper abdominal pain that often radiates to the back, accompanied by nausea, vomiting, fever, and rapid pulse. In severe cases, it can lead to organ failure and death.

GLP-1 receptor agonist medications stimulate insulin secretion from the pancreas. This mechanism can overstimulate the organ, leading to inflammation. Studies have shown an elevated risk of pancreatitis in patients taking semaglutide and other GLP-1 drugs. The FDA added pancreatitis warnings to GLP-1 drug labels, but lawsuits allege the warnings were inadequate and came too late.

Chronic pancreatitis — repeated bouts of inflammation — can cause permanent damage to the pancreas, leading to diabetes, malnutrition, and chronic pain. Patients who developed pancreatitis after starting GLP-1 medications may have grounds for a claim regardless of whether the condition resolved or became chronic.

Blood tests measuring lipase and amylase levels are the primary diagnostic tools. Elevated levels (typically 3x normal or higher) combined with characteristic symptoms confirm acute pancreatitis. CT scans or MRI may be used to assess severity and rule out complications like necrosis or pseudocysts. Medical records documenting these tests are important evidence for litigation.